Growing Body of Evidence on SImmetry SystemThese study results support the growing body of evidence on the effectiveness of the SImmetry System. The ongoing EVoluSIon Clinical Study is evaluating the impact of SImmetry on SI joint fusion and pain reduction in up to 250 patients at up to 40 sites. More than 180 patients have been enrolled to date. An early analysis of the first 50 patients published in December 2017 showed a 54 percent reduction in SI joint pain at six months as well as a 55 percent reduction in opioid use. 1 A separate CT fusion study on the SImmetry System demonstrated a 73 percent reduction in average pain over 24 months. 2 Additional data from the EVoluSIon Clinical Study will be presented at the upcoming International Society for the Advancement of Spine Surgery (ISASS) 2018 Annual Meeting taking place April 11-13 in Toronto, Canada. Approximately 20 percent of all chronic low back pain derives from the SI joint, 3 which links the base of the spine to the pelvic bone. When nonsurgical therapy is ineffective in managing SI joint pain, surgical fusion is a viable long-term option. Traditional open fixation is a complex and invasive procedure associated with considerable morbidity and risk of injury. 4 About RTI Surgical, Inc. RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI's implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com. Forward-Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements, gaining market share and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov. 1 Araghi A et al. Pain and Opioid use Outcomes Following Minimally Invasive Sacroiliac Joint Fusion with Decortication and Bone Grafting: The Evolusion Clinical Trial. Open Orthop J. 2017;11:1440-1448. 2 Cross W et al. Minimally Invasive Sacroiliac Joint Fusion: 2-Year Radiographic and Clinical Outcomes with a Principles-Based SIJ Fusion System. Open Orthop J. 2018 Jan 17;12:7-16. 3 Cohen SP et al. Sacroiliac Joint Pain: A Comprehensive Review of Epidemiology, Diagnosis and Treatment. Expert Rev Neurother. 2013; 13(1):99-116. 4 Snyder LA et al. The technological development of minimally invasive spine surgery. Biomed Res Int. 2014:293582.